Modification of the lipoxygenase pathway of arachidonic acid metabolism.
Ford-Hutchinson
A W
AW
Merck Frosst Centre for Therapeutic Research, Department of Pharmacology, Pointe Claire-Dorval, Québec, Canada.
D000818:Animals; D001094:Arachidonate 5-Lipoxygenase / Q000378:metabolism*; D001091:Arachidonate Lipoxygenases / Q000378:metabolism*; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000378:metabolism*; D001982:Bronchial Diseases / Q000188:drug therapy; D003251:Constriction, Pathologic / Q000188:drug therapy; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D016859:Lipoxygenase Inhibitors; D015394:Molecular Structure; D011422:Propionates / Q000494:pharmacology / Q000627:therapeutic use; D011804:Quinolines / Q000494:pharmacology / Q000627:therapeutic use; D011971:Receptors, Immunologic / Q000037:antagonists & inhibitors; D018077:Receptors, Leukotriene; D002722:Chlorobenzenes
D001094:Arachidonate 5-Lipoxygenase; D001091:Arachidonate Lipoxygenases; D016718:Arachidonic Acid; D001095:Arachidonic Acids; D007211:Indoles; D016859:Lipoxygenase Inhibitors; D011422:Propionates; D011804:Quinolines; D011971:Receptors, Immunologic; D018077:Receptors, Leukotriene; C060893:MK-886; D002722:Chlorobenzenes; C059141:verlukast